Mostrar el registro sencillo del ítem
dc.contributor.author
Taira, Carlos Alberto
dc.contributor.author
Opezzo, Javier A. W.
dc.contributor.author
Mayer, Marcos Alejandro
dc.contributor.author
Höcht, Christian
dc.date.available
2017-03-22T19:28:29Z
dc.date.issued
2010-01
dc.identifier.citation
Taira, Carlos Alberto; Opezzo, Javier A. W.; Mayer, Marcos Alejandro; Höcht, Christian; Cardiovascular drugs inducing QT prolongation: facts and evidence; Bentham Science Publishers; Current Drug Safety; 5; 1; 1-2010; 65-72
dc.identifier.issn
1574-8863
dc.identifier.uri
http://hdl.handle.net/11336/14202
dc.description.abstract
Acquired QT syndrome is mainly caused by the administration of drugs that prolong ventricular repolarization. On the other hand, the risk of drug-induced torsades de pointes is increased by numerous predisposing factors, such as genetic predisposition, female sex, hypokalemia and cardiac dysfunction. This adverse reaction is induced by different chemical compounds used for the treatment of a variety of pathologies, including arrhythmias. As it is known, antiarrhythmic agents and other cardiovascular drugs can prolong the QT interval, causing this adverse reaction. Of the 20 most commonly reported drugs, 10 were cardiovascular agents and these appeared in 348 of the reports (46%). Class Ia antiarrhythmic agents have frequently been linked to inducing arrhythmia, including torsades de pointes. Sotalol and amiodarone, class III antiarrhythmics, are known to prolong the QT interval by blocking IKr. Due to the severity of events caused by the therapeutic use of these drugs, in this work of revision the cardiovascular drugs that present this property and the factors and evidence will be mentioned.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Bentham Science Publishers
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.subject
Qt Interval
dc.subject
Drug Induced Torsades de Pointes
dc.subject
Antiarrhytmics Drugs
dc.subject
Amiodarone
dc.subject
Sotalol
dc.subject
Herg Channel
dc.subject.classification
Fisiología
dc.subject.classification
Medicina Básica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Cardiovascular drugs inducing QT prolongation: facts and evidence
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2017-03-21T20:14:02Z
dc.identifier.eissn
2212-3911
dc.journal.volume
5
dc.journal.number
1
dc.journal.pagination
65-72
dc.journal.pais
Emiratos Árabes Unidos
dc.journal.ciudad
Sharjah
dc.description.fil
Fil: Taira, Carlos Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología. Cátedra de Farmacología; Argentina
dc.description.fil
Fil: Opezzo, Javier A. W.. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología. Cátedra de Farmacología; Argentina
dc.description.fil
Fil: Mayer, Marcos Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología. Cátedra de Farmacología; Argentina
dc.description.fil
Fil: Höcht, Christian. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología. Cátedra de Farmacología; Argentina
dc.journal.title
Current Drug Safety
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/70534/article
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.2174/157488610789869229
Archivos asociados